Skip to main content

Maetzold Derek J's Form 4 filing

Castle Biosciences Inc (CSTL) · filed Apr 14, 2023

Accession no.
0001447362-23-000060
Filed
Apr 14, 2023
Trade date
Apr 12-13, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 14 non-derivative transactions. Open-market sales total $189.7K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Maetzold Derek JCIK 0001239501Director, Officer (Pres. & Chief Exec. Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 12, 2023Common StockSSaleDisposed−969$22.61F2−$21,909.09156,596Direct
Apr 12, 2023Common StockSSaleDisposed−484$22.61F2−$10,943.24115,862Indirect
Apr 12, 2023Common StockSSaleDisposed−484$22.61F2−$10,943.24104,757Indirect
Apr 12, 2023Common StockSSaleDisposed−242$22.61F2−$5,471.6221,370Indirect
Apr 12, 2023Common StockSSaleDisposed−242$22.61F2−$5,471.6221,371Indirect
Apr 12, 2023Common StockSSaleDisposed−242$22.61F2−$5,471.6221,370Indirect
Apr 12, 2023Common StockSSaleDisposed−242$22.61F2−$5,471.6221,363Indirect
Apr 13, 2023Common StockSSaleDisposed−1,823$22.68F9−$41,345.64154,773Direct
Apr 13, 2023Common StockSSaleDisposed−912$22.68F9−$20,684.16114,950Indirect
Apr 13, 2023Common StockSSaleDisposed−912$22.68F9−$20,684.16103,845Indirect
Apr 13, 2023Common StockSSaleDisposed−455$22.68F9−$10,319.420,915Indirect
Apr 13, 2023Common StockSSaleDisposed−455$22.68F9−$10,319.420,916Indirect
Apr 13, 2023Common StockSSaleDisposed−455$22.68F9−$10,319.420,915Indirect
Apr 13, 2023Common StockSSaleDisposed−455$22.68F9−$10,319.420,908Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This transaction was executed in multiple trades at prices ranging from $22.450 to $22.980, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 7 transactions in Table I.

F9

This transaction was executed in multiple trades at prices ranging from $22.385 to $23.040, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 7 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)